Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

VolitionRx’s NuQ® Assays Demonstrate 80% Detection Rate in Prostate Cancer

Published: Monday, March 17, 2014
Last Updated: Monday, March 17, 2014
Bookmark and Share
Study data also demonstrates ability to distinguish between prostate and colorectal cancer.

VolitionRx Limited announces data from a pilot study into the utility of VolitionRx’s NuQ® tests to diagnose prostate cancer. 

The results from the trial show that VolitionRx NuQ® assays were able to detect approximately 80 per cent of prostate cancer cases. Significantly, the trial showed that not only does the test have a high detection rate for prostate cancer, but it can differentiate between colorectal and prostate cancer. It does this by detecting the levels of epigenetically altered circulating nucleosomes in each sample, the structure of which Volition has found to be different in the two different types of cancer. For example, levels of circulating nucleosomes containing H3K9(Me)3 were elevated in colorectal cancer, but supressed in prostate cancer.  This indicates that NuQ® ELISA tests could be used to detect both prostate and colorectal cancers. 

Dr. Jake Micallef, Chief Scientific Officer at VolitionRx, will present a poster at The International Society of Oncology and Biomarkers Congress (ISOBM) in Barcelona, sharing results of the latest study into the effectiveness of NuQ® assays as an initial screening tool in detecting colorectal and now prostate cancer.  The poster abstract and a PDF of the poster is available on the VolitionRx website at: http://volitionrx.com/technologies-abstracts-papers-posters.html. 

“This is a very exciting outcome for us as we continue the development of our NuQ tests,” says Dr. Jake Micallef. “To have proof that with the right panel combination, NuQ tests can distinguish between different types of cancer as well as healthy samples, is just what we’ve been working towards. Detection of two major cancers with a blood test is a major milestone and a sound basis on which to investigate further cancers for panels of NuQ tests that detect and distinguish cancer diseases.”

NuQ® assays identify and measure circulating nucleosomes structures for the presence of epigenetic cancer signals within the blood. Results from another recent trial conducted demonstrated that the NuQ® assays were able to also detect more than 85 per cent of colorectal cancer cases with greater than 85 per cent specificity. The earlier study took samples from both healthy subjects and subjects recently diagnosed with colorectal cancer.      

Volition is carrying out several clinical trials on the effectiveness of the NuQ® assays as a cancer diagnostic tool: 

• A 4,800 patient retrospective study and an 11,000 patient prospective study into colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark. 

• A 2,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany.

• A 250 patient study into colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

VolitionRx Invests in Laboratory Automation System
Automation will accelerate analysis of blood samples for expanded colorectal cancer screening trial.
Wednesday, August 13, 2014
VolitionRx Extends Agreement with University Hospital Bonn to Include CE Mark Performance Evaluation
The agreement also doubles the Hospital’s prospective trial of 20 cancers, and adds a range of additional vital background work.
Thursday, April 24, 2014
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Alzheimer's Genetics Point To New Research Direction
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
The Epigenetic Influences of Chronic Pain
Researchers at Drexel University College of Medicine are aiming to identify new molecular mechanisms involved in pain.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!